OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press29310.17650/1818-8346-2018-13-2-93-99BASIC RESEARCHФУНДАМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ В ПРАКТИЧЕСКОЙ МЕДИЦИНЕ НА СОВРЕМЕННОМ ЭТАПЕGPIIB ALLELIC POLYMORPHISM AS A FACTOR ASSOCIATED WITH THE PROBABILITY OF IMMUNE THROMBOCYTOPENIA AND THE SEVERITY OF HEMORRHAGIC SYNDROMEАЛЛЕЛЬНЫЙ ПОЛИМОРФИЗМ ГЕНА GPIIB КАК ФАКТОР, АССОЦИИРОВАННЫЙ С ВЕРОЯТНОСТЬЮ РАЗВИТИЯ ИММУННОЙ ТРОМБОЦИТОПЕНИИ И ТЯЖЕСТЬЮ ГЕМОРРАГИЧЕСКОГО СИНДРОМАZotovaI. I.ЗотоваИ. И.
Russian Federation

16 Vtoraya Sovetskaya St., 191024 Saint Petersburg

Ирина Ивановна Зотова

191024 Санкт-Петербург, 2-я Советская ул., 16

hemzot@mail.ruKapustinS. I.КапустинС. И.
Russian Federation

16 Vtoraya Sovetskaya St., 191024 Saint Petersburg

191024 Санкт-Петербург, 2-я Советская ул., 16

GritsaevS. V.ГрицаевС. В.
Russian Federation

16 Vtoraya Sovetskaya St., 191024 Saint Petersburg

191024 Санкт-Петербург, 2-я Советская ул., 16

MineevaN. V.МинееваН. В.
Russian Federation

16 Vtoraya Sovetskaya St., 191024 Saint Petersburg

191024 Санкт-Петербург, 2-я Советская ул., 16

KrobinetsI. I.КробинецИ. И.
Russian Federation

16 Vtoraya Sovetskaya St., 191024 Saint Petersburg

191024 Санкт-Петербург, 2-я Советская ул., 16

SidorovaZh. Yu.СидороваЖ. Ю.
Russian Federation

16 Vtoraya Sovetskaya St., 191024 Saint Petersburg

191024 Санкт-Петербург, 2-я Советская ул., 16

BessmeltsevS. S.БессмельцевС. С.
Russian Federation

16 Vtoraya Sovetskaya St., 191024 Saint Petersburg

191024 Санкт-Петербург, 2-я Советская ул., 16

ChechetkinA. V.ЧечеткинА. В.
Russian Federation

16 Vtoraya Sovetskaya St., 191024 Saint Petersburg

191024 Санкт-Петербург, 2-я Советская ул., 16

Russian Scientific Research Institute of Hematology and Transfusiology under the Federal Medico-Biological AgencyФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии ФМБА России»1207201813293991607201816072018https://oncohematology.abvpress.ru/ongm/article/view/293

Russian Scientific Research Institute of Hematology and Transfusiology under the Federal Medico-Biological Agency; 16 Vtoraya Sovetskaya St., 191024 Saint Petersburg, Russia

Polymorphism of platelet glycoproteins GPIIIa (T1565C), GPIba (T434C), GPIIb (T2622G) and GPIa (A1648G) genes, responsible for the formation of alloantigenic platelet systems HPA-1, -2, -3 and -5, in patients with chronic immune thrombocytopenia (ITP) and in control group (CG) was investigated. Among ITP patients, the proportion of homozygotes of the GPIIb 2622 GG (HPA-3b/3b) gene was more than 2 times higher than in CG: 23.9 % versus 11.4 % (odds ratio (OR) = 2.4, 95 % confidence interval (CI): 1.0–5.8, p = 0.05). The frequency of HPA-3a/3a (GPIIb 2622TT,843Ile/Ile) genotype was higher in ITP patients with 2–3rd degrees of hemorrhagic syndrome (HS): 55.6% versus 25.0% in the group with 0–1st degree of HS (OR = 3.8, 95 % CI: 1.3–10.7, p = 0.02). The obtained data suggest the effect of T2622G polymorphism GPIIb gene both on development of disease (2622 GG genotype), and on serious manifestations of HS (2622 TT genotype), which allows considering this polymorphism as unfavorable prognostic criterion in ITP patients.

Проведено исследование полиморфизма генов тромбоцитарных гликопротеинов GPIIIa (Т1565С), GPIba (Т434С), GPIIb (T2622G) и GPIa (A1648G), ответственных за формирование аллоантигенных систем тромбоцитов НРА-1, -2, -3 и -5, у больных хронической иммунной тромбоцитопенией (ИТП) и контрольной группы. Среди больных ИТП доля гомозигот гена GPIIb 2622 GG (HPA-3b/3b) более чем в 2 раза превысила таковую в КГ: 23,9 % против 11,4 % соответственно (отношение шансов (ОШ) = 2,4, 95 % доверительный интервал (ДИ): 1,0–5,8; p = 0,05). Частота генотипа HPA-3a/3a (GPIIb 2622TT,843Ile/Ile) оказалась выше у больных ИТП с геморрагическим синдромом (ГС) 2–3-й степени: 55,6 % против 25,0 % в группе с ГС 0–1-й степени (ОШ = 3,8, 95 % ДИ: 1,3–10,7, p = 0,02). Полученные данные свидетельствуют о влиянии полиморфизма T2622G гена GPIIb на развитие как самого заболевания (генотип 2622 GG), так и сопровождающих его тяжелых проявлений ГС (генотип 2622 TT), что позволяет рассматривать указанный полиморфизм в качестве прогностического критерия неблагоприятного течения ИТП.

immune thrombocytopeniahemorrhagic syndromegene polymorphismGPIIb geneHPA-3b/3b (GPIIb 2622 GG) genotypeHPA-3a/3a (GPIIb 2622TT) genotypeиммунная тромбоцитопениягеморрагический синдромполиморфизм геновген GPIIbгенотип HPA-3b/3b (GPIIb 2622 GG)генотип HPA-3а/3а (GPIIb 2622TT)George J.N., Woolf S.H., Raskob G.E. et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88(1):3–40. PMID: 8704187.Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. British Committee for Standards in Haematology General Haematology Task Force. Br J Haematol 2003;120(4):574–96. PMID: 12588344.Cohen Y.C., Djulbegovic B., Shamai-Lubovitz O. et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000;160(11):1630–8. PMID: 10847256.El Ghannam D., Fawzy I.M., Azmy E. et al. Relation of interleukin-10 promoter polymorphisms to adult chronic immune thrombocytopenic purpura in a cohort of Egyptian population. Immunol Invest 2015;44(7):616–26. DOI: 10.3109/08820139.2015.1064948. PMID: 26436850.Li H., Zhou Z., Tai W. et al. Decreased frequency of IL-17F rs763780 site allele G is associated with genetic susceptibility to immune thrombocytopenia in a Chinese population. Clin Appl Thromb Hemost 2017;23(5):466–71. DOI: 10.1177/1076029615618022. PMID: 26620416.Zhou H., Yang J., Liu L. et al. The polymorphisms of tumor necrosis factor-induced protein 3 gene may contribute to the susceptibility of chronic primary immune thrombocytopenia in Chinese population. Platelets 2016;27(1):26–31. DOI: 10.3109/09537104.2015.1022142. PMID: 25806576.Saitoh T., Kasamatsu T., Inoue M. et al. Interleukin-10 gene polymorphism reflects the severity of chronic immune thrombocytopenia in Japanese patients. Int J Lab Hematol 2011;33(5):526–32. DOI: 10.1111/j.1751-553X.2011.01320.x. PMID: 21463487.Pehlivan M., Okan V., Sever T. et al. Investigation of TNF-alpha, TGF-beta 1, IL-10, IL-6, IFN-gamma, MBL, GPIA, and IL1A gene polymorphisms in patients with idiopathic thrombocytopenic purpura. Platelets 2011;22(8):588–95. DOI: 10.3109/09537104.2011.577255. PMID: 21591983.Li J., Ma S., Shao L. et al. Inflammationrelated gene polymorphisms associated with primary immune thrombocytopenia. Front. Immunol 2017;8:744. DOI: 10.3389/fimmu.2017.00744. PMID: 28702029.Lyu M., Li Y., Hao Y. et al. Stromal cell-derived factor-1 rs2297630 polymorphism associated with platelet production and treatment response in Chinese patients with chronic immune thrombocytopenia. Platelets 2016;27(4):338–43. DOI: 10.3109/09537104.2015.1103368. PMID: 26587874.Xuan M., Li H., Fu R. et al. Association of ABCB1 gene polymorphisms and haplotypes with therapeutic efficacy of glucocorticoids in Chinese patients with immune thrombocytopenia. Hum Immunol 2014;75(4):317–21. DOI: 10.1016/j.humimm.2014.01.01. PMID: 24486577.Provan D., Stasi R., Newland A.C. et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115(2):168–86. DOI: 10.1182/blood-2009-06-225565. PMID: 19846889.Melikyan A.L., Pustovaya E.I., Tsvetaeva N.V. et al. National clinical recommendations for diagnosis and therapy of idiopathic thrombocytopenic purpura (primary immune thrombocytopenia) in adults (2016 edition). Gematologiya i transfuziologiya = Нematology and transfusiology 2017;62(1, suppl.1):1–24. (In Russ.).Меликян А.Л., Пустовая Е.И., Цветаева Н.В. и др. Национальные клинические рекомендации по диагностике и лечению первичной иммунной тромбоцитопении (идиопатической тромбоцитопенической пурпуры) у взрослых (редакция 2016 г.). Гематология и трансфузиология 2017;62 (1, suppl.1):1–24.Miller A.B, Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981;47(1):207–14.PMID: 7459811.Neunert C., Noroozi N., Norman G. et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost 2015;13(3):457–64. DOI: 10.1111/jth.12813. PMID: 25495497.Stasi R., Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004;79(4):504–22. DOI: 10.4065/79.4.504. PMID: 15065616.Gernsheimer T. Epidemiology and pathophysiology of immune thrombocytopenic purpura. Eur J Haematol Suppl 2008;69: 3–8. DOI: 10.1111/j.1600-0609.2007.00998.x. PMID: 18211567.Despotovic J.M., Polfus L.M., Flanagan J.M. et al. Genes influencing the development and severity of chronic ITP identified through whole exome sequencing. Blood 2015;126(23):73.Carter A.M., Catto A.J., Bamford J.M. et al. Association of the platelet glycoprotein IIb HPA-3 polymorphism with survival after acute ischemic stroke. Stroke 1999;30(12):2606–11.PMID: 10582985.Duan H., Cai Y., Sun X. Platelet glycoprotein IIb/IIIa polymorphism HPA-3 b/b is associated with increased risk of ischemic stroke in patients under 60 years of age. Med Sci Monit 2012;18(1):CR19–24. PMID: 22207115.Liu H., Wang Y., Zheng J. et al. Platelet glycoprotein gene Ia C807T, HPA-3, and Ibα VNTR polymorphisms are associated with increased ischemic stroke risk: Evidence from a comprehensive meta-analysis. Int J Stroke 2017;12(1):46–70. DOI: 10.1177/1747493016672085. PMID: 28004990.Lyman S., Aster R.H., Visentin G.P., Newman P.J. Polymorphism of human platelet membrane glycoprotein IIb associated with the Baka/Bakb alloantigen system. Blood 1990; 75(12):2343–48.PMID: 2350579.